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PCardiac Imaging
Prognostic Score for Prediction of
ardiac Mortality Risk After Adenosine
tress Myocardial Perfusion Scintigraphy
ory Hachamovitch, MD, MSC, FACC,* Sean W. Hayes, MD,† John D. Friedman, MD, FACC,†
shac Cohen, PHD, Daniel S. Berman, MD, FACC†
os Angeles, California
OBJECTIVES We sought to derive and validate a score to estimate risk after adenosine stress.
BACKGROUND Maximizing the prognostic information extracted from adenosine stress myocardial perfusion
scintigraphy, a commonly performed test, is often challenging for referring physicians.
METHODS A split-set validation of a score predicting cardiovascular mortality was performed in 5,873
consecutive patients studied by adenosine stress, dual-isotope single-photon emission
computed tomography (SPECT; follow-up 94% complete, mean 2.2  1.1 years).
RESULTS On follow-up, 387 cardiac deaths occurred (6.6%). The Cox proportional hazards model most
predictive of cardiac death included age, % myocardium ischemic, % myocardium fixed, early
revascularization, dyspnea, diabetes mellitus, rest and peak stress heart rates, abnormal rest
electrocardiogram (ECG), and an interaction between % myocardium ischemic and early
revascularization (chi-square  376). The final prognostic score was calculated as follows:
(age [decades]  5.19)  (% myocardium ischemic [per 10%]  4.66)  (% myocardium
fixed [per 10%]  4.81)  (diabetes mellitus  3.88)  (if patient treated with early
revascularization, 4.51)  (if dyspnea was a presenting symptom, 5.47)  (resting heart rate
[per 10 beats]  2.88)  (peak heart rate [per 10 beats]  1.42)  (ECG score  1.95) 
(if patient treated with early revascularization, % myocardium ischemic [per 10%]  4.47).
Scores of49, 49 to 57, and57 identified low, intermediate, and high risk (0.9%, 3.3%, and
9.5% cardiac death/year, respectively). Score results further risk stratified patients with respect
to cardiac death in all categories of SPECT abnormality.
CONCLUSIONS We derived and validated a score incorporating data available after adenosine stress perfusion
SPECT. This score maximizes the prognostic information extracted from this test and may
enhance the application of this test as part of an overall strategy. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.06945:722–9) © 2005 by the American College of Cardiology Foundation
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bumerous previous studies have ascertained the indepen-
ent and incremental prognostic value of pharmacologic
tress myocardial perfusion single-photon emission com-
uted tomography (SPECT), or MPS, in various patient
ubsets (1–4). Although the prognostic implications of
See page 730
denosine MPS have been shown to be equivalent to those
btained from exercise MPS (1), the results of the former
re often more challenging for clinicians to apply to clinical
anagement decisions, due to the absence of information
n exercise tolerance and stress-induced symptoms, as well
s the altered accuracy of stress-induced electrocardio-
raphic (ECG) changes. Patients referred to pharmacologic
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chool of Medicine, University of Southern California; and †Department of Imaging
Division of Nuclear Medicine), Department of Medicine (Division of Cardiology),
he CSMC Burns & Allen Research Institute, Cedars-Sinai Medical Center, and
epartment of Medicine, University of California at Los Angeles, School of
edicine, Los Angeles, California. This work was supported in part by grants from
ristol-Myers Squibb Medical Imaging, Inc., Billerica, Massachusetts, and Fujisawa
ealthcare, Inc., Deerfield, Illinois. Dr. James E. Udelson acted as Guest Editor for
his paper.a
Manuscript received November 26, 2002; revised manuscript received August 23,
004, accepted August 30, 2004.tress are at greater baseline clinical risk, have more comor-
idities, and are more frequently older, diabetic, female, and
ith previous coronary artery disease (CAD), further ob-
uscating the interpretation of adenosine stress results and
heir incorporation into clinical strategies (1–5). The finding
hat for any perfusion defect’s extent and severity, patient
isk varies widely as a function of multiple historical,
linical, and stress test characteristics further complicates
atters (6–8).
Maximizing the prognostic information extracted from
esting mandates incorporation of multiple, complementary
ata elements. In daily practice, however, combining clini-
al, historical, and stress test data remains a challenge for
linicians, particularly with pharmacologic stress testing. A
umber of previous studies have examined the value of
ggregate or composite variables summarizing clinical
nd/or exercise treadmill test (ETT) information for pre-
icting patient risk (9,10). Further, previous studies have
hown that by combining stress test and clinical data,
stimates of risk with alternative therapeutic approaches can
e generated, thus estimating, a priori, a therapeutic survival
enefit (11). It would enhance the clinical value of this
pproach if estimates of patient benefit with revasculariza-
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rognostic score.
A validated prognostic adenosine stress score incorporat-
ng clinical, historical, and nuclear variables may enhance
hysicians’ understanding of adenosine stress results and
mprove their incorporation into clinical strategies. Thus,
he goal of this study was to derive and validate a prognostic
denosine score incorporating clinical, stress test, and MPS
ata for prediction of cardiovascular mortality and treatment
enefit.
ETHODS
atients. All patients who underwent rest thallium-201
Tl-201)/adenosine technetium-99m (Tc-99m) sestamibi
ual-isotope MPS at Cedars-Sinai Medical Center for
valuation of suspected or known CAD between 1991 and
998 (each patient considered once) were identified (Fig. 1).
atients with known valvular heart disease or nonischemic
ardiomyopathy were excluded, and follow-up was 94%. Of
his population, 4,784 (81%) underwent adenosine stress
ithout walking as an adjunct to testing, constituting the
ohort for primary analyses of this study. In addition, 3,294
atients (56%) were identified who underwent adenosine
tress during the period when patients who were able to
alk did so as an adjunct to stress (July 1995 to May 1998).
his patient group was used in a secondary analysis modi-
ying the prognostic score to include a factor ability to walk.
his study was approved by Cedars-Sinai Medical Center’s
Abbreviations and Acronyms
CAD  coronary artery disease
ECG  electrocardiogram
ETT  exercise treadmill test
MPS  myocardial perfusion single-photon emission
computed tomography
SPECT single-photon emission computed tomography
Tc-99m technetium-99m
Tl-201  thallium-201
igure 1. Flow chart defining the number of patients included/excluded fora
arious criteria and the definition of cohorts for the primary and secondary
nalyses.nstitutional Review Board. The patients included in the
urrent study have been included in previous studies from
ur group (2,4,6–8,12).
tress testing, image acquisition, processing, and inter-
retation. Throughout this study, we used protocols that
e have described at length elsewhere (2,4,6–8,12–16). All
atients were requested to be withdrawn from nitrates for
h, calcium blockers for 24 h, and beta-blockers for 48 h at
he time of MPS and were instructed not to consume
affeine-containing products for 24 h before testing.
ual-isotope adenosine MPS protocol. Thallium-201
3.0 to 4.5 mCi) was injected intravenously at rest (with
ose variation based on patient weight), and SPECT
cquisition started 10 min after radioisotope injection. All
PECT acquisitions were performed, as previously de-
cribed (circular or elliptical 180° acquisition for 64 projec-
ions at 25 s/projection for Tc-99m or 35 s/projection for
l-201) without attenuation or scatter correction (16).
Adenosine was infused at a rate of 140 g/kg body
eight per minute for 5 to 6 min with Tc-99m sestamibi
25 to 40 mCi) injected intravenously at the end of the
econd or third minute of infusion (for 5- and 6-min
rotocols, respectively). Patients undergoing adenosine
tress with walking (33% of patients tested from July 1995
o May 1998) walked at a 0 to 10° grade and 1 to 1.7 mph.
uring adenosine infusion, the 12-lead ECG was recorded
ach minute, and leads aVF, V1, and V5 were continuously
onitored. Semiquantitative visual interpretation of MPS
mages was done using our standard 20-segment, 5-point
coring system (16).
erived variables. Summed stress, rest, and difference
cores derived from 20-segment scores (16) were converted
o percent total myocardium (% myocardium) involved with
tress, ischemic, or fixed defects (summed scores/80 [max-
mum potential score  4  20]  100). A summed stress
core 4 (5% myocardium) defined normal scans, 4 to 8
5% to 10% myocardium) represented mildly abnormal
cans; and8 (10% myocardium) indicated moderately to
everely abnormal scans.
An abnormal rest ECG was defined as the absence of any
bnormality, except sinus tachycardia, sinus bradycardia,
arly repolarization abnormality, and isolated, single prema-
ure atrial or ventricular contractions.
ollow-up data. Follow-up was performed at 2.2  1.1
ears (all 1 year) by trained personnel. The end point
xamined was cardiac death, confirmed by a review of the
eath certificate, hospital chart, or physician’s records. Early
evascularization was defined as performance of percutane-
us coronary intervention or coronary artery bypass graft
urgery 60 days after MPS (17).
tatistical analysis. Baseline characteristics were described
n terms of median (25th, 75th percentiles) for continuous
ariables and frequencies for categorical variables. The
ormer was compared using the Wilcoxon rank-sum test
nd the latter using a chi-square test for comparisons of
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Adenosine Stress MPS Prognostic Score March 1, 2005:722–9iscrete variables. A value p  0.05 was considered statis-
ically significant.
core derivation and validation. Patients were randomly
ssigned to training and validation groups (n  2,369 and
,415, respectively). Rest ECG findings predictive of car-
iac death were modeled to define an ECG score, prognos-
ically summarizing the ECG data. In the training set, a
ox proportional hazards model (18) was used to assess the
elationship between individual clinical, historical, and
denosine stress data and cardiovascular death. This model
as bootstrapped (400 iterations, 50% of population per
ample) to identify variables for the final Cox model (19,20).
eta coefficients from this final Cox model were used as
eighting factors (each covariate weighted in proportion to
ts predictive value) to create a score. Cox modeling was
epeated using the combined training plus validation. This
core was tested in the training and validation sets, and the
elationship between the score and risk of cardiovascular
eath was assessed.
Using this same approach, the prognostic score was
urther adjusted by incorporating data from a subset of
atients who underwent testing after initiation of walking
denosine protocols. Similarly, we also derived and validated
simplified score that would require less information and
ake for easier calculation. In this, we did not consider
ost-MPS patient management nor any interactions, but
nly elements available at the time of interpretation (MPS
esults, age, presenting symptoms, ECG). Of note, because
his simplified score could not be adjusted for treatment,
atients who underwent revascularization in the first 60 days
fter the nuclear study were censored from analyses.
At all steps, care was given to examination of the
ssumptions of proportional hazards, linearity, and additiv-
ty, as appropriate (19). The S-PLUS 2000 (MathSoft, Inc.,
eattle, Washington) was used for all analyses. Post-hoc
ample size calculation was performed (21).
ESULTS
atient characteristics. Patient characteristics were virtu-
lly identical in the training and validation sets (Table 1).
imilarly, there were no differences between training and
alidation sets undergoing MPS at the time walking aden-
sine protocols were performed.
utcome events. During follow-up, 387 cardiac deaths
ccurred (6.6% mortality rate, 3.0%/year). In patients un-
ergoing non-walking adenosine stress, 352 cardiac deaths
ccurred (7.4%), with an additional 35 cardiac deaths in
atients undergoing walking adenosine protocols (3.2%).
arly revascularization occurred in 9.0% of patients under-
oing non-walking and 11.3% of patients undergoing MPS
hen walking adenosine protocols were performed.
ultivariable survival analysis. ELECTROCARDIOGRAPHIC
CORE. A number of rest ECG variables were found to be
rognostically important by univariable Cox modeling (Ta-
le 2). The presence of right or left bundle branch block, interior or posterior hemiblock, QRS interval 0.12 ms,
nd second- or third-degree atrioventricular block were
ombined into a single variable (“any block”), which was
ore predictive than any of its constituents. The most
redictive multivariable model of ECG variables for cardiac
eath included “any block” (beta  0.628), left ventricular
ypertrophy with repolarization abnormalities (beta 
.724), premature ventricular beat(s) (beta  0.832), and
onspecific ST-T wave changes (beta  0.331). Based on
hese results, the weighted ECG score was 0.628 (if “any
lock” was present)  0.724 (if left ventricular hypertrophy
ith repolarization)  0.832 (if premature ventricular con-
raction[s])  0.331 (if nonspecific ST-T wave changes).
VERALL SCORE. The model most predictive of cardiac
eath in the training set is shown in Table 3 (global
hi-square  376). On the basis of these beta coefficients,
elative weights and directions were assigned to each covari-
te, when combined to define a prognostic score. Annual-
able 1. Patient Characteristics in Training and Validation
ubsets
Derivation
Set
(n  2,369)
Validation
Set
(n  2,415)
emographic risk factors
Age (yrs) 73 (65, 79) 73 (66, 80)
Male gender 51% 49%
Hypertension 58% 57%
Diabetes 25% 24%
Family history of CAD 23% 22%
Hypercholesterolemia 41% 41%
Smoking 12% 12%
Angina 48% 47%
Shortness of breath 10% 10%
Abnormal rest ECG 82% 81%
edications
Beta-blocker 13% 12%
Calcium channel blocker 16% 15%
Nitrate (any) 11% 11%
Digoxin 11% 11%
linical history
History of MI 26% 24%
History of PCI 15% 13.2%
History of CABG 21% 18.6%
History of revascularization 9.2% 8.9%
History of CAD 49% 49%
emodynamics
Rest systolic BP (mm Hg) 151 (133, 169) 150 (131, 169)
Rest diastolic BP (mm Hg) 80 (71, 88) 79 (70, 88)
Stress systolic BP (mm Hg) 135 (115, 154) 134 (115, 154)
Stress diastolic BP (mm Hg) 70 (61, 79) 70 (61, 80)
Rest HR (per min) 71 (62, 79) 70 (61, 79)
Stress HR (per min) 85 (75, 97) 85 (74, 98)
tress test
Maximum ST-segment change 0 (0, 0) 0 (0, 0)
%myocardium abnormal 8 (0, 18) 5 (0, 17.5)
%myocardium fixed 0 (0, 5) 0 (0, 4)
%myocardium ischemic 4 (0, 10) 2.5 (0, 10)
P  blood pressure; CAD  coronary artery disease; CABG  coronary artery
ypass surgery; ECG  electrocardiogram; HR  heart rate; MI  myocardial
nfarction; PCI  percutaneous coronary interventions.zed cardiac death rates by score quartile reveal similar
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Fig. 2).
The final weights for the adenosine score were deter-
ined by recalculating the coefficients from the Cox model
sing the covariates listed in Table 3 in the overall patient
et (n  4,784, 372 cardiac deaths). The results of this
odel reveal minor changes in the coefficients for early
evascularization and an abnormal ECG. After these mod-
fications, the annualized cardiac mortality rates in prognos-
ic score quartiles (Fig. 2) did not materially change in
omparison to the mortality rates in initial prognostic score
uartiles in the training and validation sets.
The final prognostic score was calculated as follows: (age
decades]  5.19)  (% myocardium ischemic [per 10%] 
.66)  (% myocardium fixed [per 10%]  4.81)  (if
able 2. Univariable Cox Proportional Hazards Analysis of
lectrocardiogram Variables
Covariate Chi-Square
trial enlargement 0.86
onspecific ST-T wave changes 0.8
V hypertrophy 6.4*
V hypertrophy with repolarization abnormalities 8.9*
V hypertrophy without repolarization abnormalities 2.5
trial fibrillation or flutter 3.8*
trial fibrillation 0.9
remature ventricular beat(s) 9.7*
efinite or possible MI 6.0*
yocardial Infarction (Q waves) 12.3*
inus tachycardia 14.6*
inus bradycardia 7.1*
irst degree AV block 0.05
econd degree AV block (any type) 6.0*
nterior or posterior hemiblock 9.5*
ncomplete bundle branch block 0.05
ight bundle branch block 1.3
eft bundle branch block 3.5
ny bundle branch block 2.1
ny block† 12.6*
aced rhythm (any) 1.5
ny bundle or paced rhythm 3.3
p  0.05; †right or left bundle branch block, anterior or posterior hemiblock, QRS
0.12, second- or third-degree atrioventricular (AV) block.
able 3. Regression Coefficients and Weightings for Covariates
rom Multivariable Modeling
Regression Coefficient
Training Set Overall Set
ge* 0.5771 0.5193
myocardium ischemic† 0.4223 0.4663
myocardium fixed† 0.5021 0.4813
iabetes mellitus 0.3057 0.3878
arly revascularization 0.5304 0.4508
yspnea 0.5574 0.5468
est HR 0.0260 0.0288
eak HR 0.0127 0.0142
eighted ECG score 0.2001 0.1953
myocardium ischemic 
early revascularization
0.3911 0.4467Per decade of age; †per 10% defect.
ECG  electrocardiogram; HR  heart rate.
3
6iabetes mellitus, 3.88)  (if patient treated with early
evascularization, 4.51)  (if dyspnea was a presenting
ymptom, 5.47)  (resting heart rate [per 10 beats]  2.88)
(peak heart rate [per 10 beats]  1.42)  (ECG score 
.95)  (if patient treated with early revascularization, %
yocardium ischemic [per 10%]  4.47). The prognostic
core cut points that correspond to widely used risk catego-
ies (low, intermediate, and high risk defined as1%, 1% to
%, and 3% risk, respectively) were 49, 49 to 57, and
57 (0.9%, 2.8%, and 6.7% cardiac death/year, respec-
ively). The relationship between two-year Kaplan-Meier
urvival free of cardiac death and the final prognostic score
s shown in Figure 3.
This score identified 388 patients (8.1% of cohort) as
aving 5% predicted improvement in survival with revas-
ularization over medical therapy, and 679 patients (14.2%)
s having 2.5% predicted improvement in survival with
evascularization over medical therapy.
ubgroup analysis. The observed annualized cardiac death
ates increased between low, intermediate, and high prog-
ostic score categories in multiple patient subsets (Table 4).
igure 2. Rates of cardiac death (expressed per year of follow-up) in
uartiles of prognostic score (p  0.001 for all three groups across
uartiles). Solid bars  training set; open bars  validation set; cross-
atched bars  overall set with recalculated scores.
igure 3. Kaplan-Meier two-year survival as a function of prognostic score
n the overall population (p  0.0001 [log-rank] across scores). Bars 
5% confidence intervals. These bars are centered at the mean prognostic
core values of seven subgroups (mean value and number of patients): 1)
4.4, n  387; 2) 42.3, n  710; 3) 49.1, n  1,528; 4) 55.3, n  909; 5)
0.2, n  601; 6) 65.9, n  458; and 7) 74.9, n  163.
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Adenosine Stress MPS Prognostic Score March 1, 2005:722–9imilarly, this score further risk stratified patients with
ormal, mildly abnormal, and moderate to severely abnor-
al MPS results, also indicating the presence of incremen-
al value of this score over MPS results alone (Fig. 4).
implified prognostic score. Using a methodologic ap-
roach similar to that described subsequently, we also
erived and validated a simplified score considering only
lements that would be available at the time the scan was
nterpreted, and incorporating neither post-MPS patient
anagement nor any interactions. This model included the
ovariates shown in Table 5 (overall model chi-square 
45). The simplified final prognostic score was calculated as
ollows: (age [years]) (% myocardium ischemic)  (%
yocardium fixed)  10 (if dyspnea was a presenting
ymptom) (resting heart rate 0.5) (peak heart rate
.5)  30 (if rest ECG is abnormal). Figure 5 shows the
elationship between Kaplan-Meier two-year survival free of
ardiac death and this simplified prognostic score.
Patients were risk stratified by the simplified score as low,
ntermediate, and high risk with respect to the annual risk of
ardiac death. A low score (80) defined 1,143 patients as
ow risk (0.6% cardiac death/year), intermediate scores (80
o 100) defined 1,380 patients as intermediate risk (2.1%
ardiac death/year), and high scores (100) defined 2,261
atients as high risk (5.6% cardiac death/year). Within each
f these three risk strata defined by the simplified score, the
ore complex score was able to successfully restratify signifi-
ant numbers of patients (low-risk subgroup: 14% of all
ow-risk patients as 1% risk [1.9%]; intermediate-risk sub-
roup: low complex score identified 51% of intermediate-risk
atients as lower risk [p  0.03]; high-risk subgroup:
omplex score reclassified 31% as intermediate risk and
.2% as low risk [p  0.001 vs. high-risk complex score]).
xpressed statistically, the overall model (Table 3) had a
-index of 0.79, whereas the simplified score model had a
-index of 0.76. Finally, the simple score is generalizable
nly to patients treated medically after MPS and cannot
dentify post-MPS therapeutic differences.
alking adenosine protocols. The complex score was
eassessed in 3,294 patients who underwent adenosine stress
uring the period when walking was used when possible as
Table 4. Subgroup Analysis Within Prognostic
Factor Subset
Gender Men
Women
Diabetes mellitus Present
Absent
History of CAD Present
Absent
Symptoms Shortness of breath
Angina
Neither
Values represent annual cardiac death rate (N). History of coro
or revascularization. p  0.05 for all comparisons between ln adjunct (July 1995 to May 1998). Using the training set
S
f this subset (1,634 patients, 99 cardiac deaths), the 10
ariables in the complex score were entered into a Cox
odel along with the dichotomous variable “walk” (0 
on-walking adenosine; 1  walking adenosine). The
esults revealed that the coefficients for the 10 variables in
he score were stable, and the use of a walking protocol
dentified patients at a lower risk (coefficient: 0.7803, p 
.002; global chi-square  142, p  0.00001). Annualized
ardiac death rates for patients in the lower quartiles of the
raining and validation sets were 0.1% and 0.3%, 0.9% and
.1%, and 3.0% and 2.7%, and in the highest quartile, 7.8%
nd 9.3%, respectively The final prognostic score incorpo-
ating the option for walking adenosine studies was calcu-
ated as follows: (age [decades]  5.19)  (% myocardium
schemic [per 10%]  4.66)  (% myocardium fixed [per
0%]  4.81)  (diabetes mellitus  3.88)  (if patient
reated with early revascularization, 4.51)  (if dyspnea was
presenting symptom, 5.47)  (resting heart rate [per 10
eats]  2.88)  (peak heart rate [per 10 beats]  1.42) 
ECG score  1.95)  (if patient treated with early
evascularization, % myocardium ischemic [per 10%] 
.47)  (if patient underwent walking as an adjunct to
denosine stress, 7.80). Figure 6 shows the relationship
igure 4. Rates of cardiac death (expressed per year of follow-up) in
atients with low (49), intermediate (49 to 57), and high (57)
rognostic scores (*p  0.001 across three prognostic score categories).
re Categories
Prognostic Adenosine Score Category
Low Intermediate High
1.2% 3.7% 9.7%
0.7% 3.3% 11.0%
1.5% 3.7% 9.7%
0.8% 3.4% 10.4%
1.4% 4.2% 10.4%
0.7% 2.8% 9.7%
1.8% 3.7% 10.7%
1.2% 3.8% 8.0%
0.5% 3.1% 12.0%
rtery disease (CAD) is defined as prior myocardial infarction
termediate, and high prognostic score categories.Scoolid bars  training set; open bars  validation set; cross-hatched bars
overall set with recalculated scores.
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March 1, 2005:722–9 Adenosine Stress MPS Prognostic Scoreetween Kaplan-Meier two-year survival free of cardiac
eath, and this modified the prognostic score.
ample size considerations. Post-hoc sample size calcula-
ions revealed that a sample size of 2,084 patients per subset
ould have been required to achieve 80% power to detect a
% difference in absolute event rates from the independently
plit samples. The current study had 90% power with a
wo-sided test at alpha  0.05 to detect a 3% difference in
bsolute event rates from the independently split samples.
ISCUSSION
n this study, we demonstrate that multiple sources of
rognostic information derived from MPS can be summa-
ized by a single score potentially utilized in daily practice.
o the best of our knowledge, this is the first such score
ncorporating MPS results, as well as the first comprehen-
ive score to be applied to pharmacologic stress. This score
s closely associated with the risk of cardiac death and
ignificantly risk stratifies patients with any MPS result,
ielding incremental information over MPS results alone.
y including a term for survival with revascularization early
fter MPS, separate estimates for survival with revascular-
zation and medical therapy after adenosine stress MPS can
e calculated, enhancing post-test patient management.
Table 5. Beta Coefficients From the Training
Trainin
Regression
Coefficient
Age 0.0407
% myocardium ischemic 0.0472
% myocardium fixed 0.0424
Dyspnea 0.4823
Rest HR 0.0368
Peak HR 0.0191
Abnormal rest ECG 1.2142
Abbreviations as in Table 3.
igure 5. Kaplan-Meier two-year survival as a function of the simplified
rognostic score in the population examined (p  0.0001 [log-rank] across
cores). These bars are centered at the mean prognostic score values of five3
5
ubgroups (mean value and number of patients): 1) 46.5, n  408; 2) 67.3,
 506; 3) 82.9, n  807; 4) 97.4, n  1,161; and 5) 123.9, n  1,902.urther, we extended this score to also include walking
denosine protocols, a recent, commonly used enhancement
f vasodilator stress protocols, thus extending the applica-
ion of this score to a wider patient group and, for the first
ime, demonstrating the prognostic value of MPS for this
rotocol.
omparison with previous studies. Several previous stud-
es have derived and validated prognostic composite vari-
bles to summarize clinical or ETT data using either
ultivariate (10,22–24) or bayesian (9) methods that have
ubsequently been revalidated in external cohorts after the
nitial derivation and validation. Other scores have also been
erived for anatomic end points and later validated toward
rognostic end points (5). We have also extended the
oncept of predictive instruments that incorporate a thera-
eutic term (to predict not only risk but also differential
reatment benefit) from the therapeutic realm into a diag-
ostic testing milieu (11).
ole of predictive instruments. Predictive instruments
erve a variety of roles and applications in health care.
mportant issues in their development and planning include
igure 6. Kaplan-Meier two-year survival as a function of prognostic score
n the population examined during the time period that walking adenosine
tress was performed (p  0.0001 [log-rank] across scores). Bars represent
5% confidence intervals. These bars are centered at the mean prognostic
core values of seven subgroups (mean value and number of patients): 1)
alidation Sets for the Simplified Model
Overall Set
Relative
Weight
Regression
Coefficient
Relative
Weight
1 0.0547 1
1 0.0401 1
1 0.0540 1
10 0.5998 10
0.5 0.0260 0.5
0.5 0.0118 0.5
25 1.6690 30and V
g Set0.5, n  445; 2) 39.8, n  620; 3) 45.6, n  551; 4) 50.5, n  556; 5)
7.2, n  792; 6) 65.6, n  218; and 7) 73.5, n  112.
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Adenosine Stress MPS Prognostic Score March 1, 2005:722–9he target audience (which type of physician will employ a
articular score), the complexity of the score, and the cohort
nd disease to be evaluated. The scores derived and vali-
ated in the current study are designed for use by physicians
nterpreting and reporting adenosine MPS. With further
alidations, these scores can be incorporated into reporting,
hus potentially benefiting patients undergoing MPS and
ssisting physicians in making better medical decisions. The
ata elements these scores require and the need to code and
ollect these data in a particular fashion are potential
imitations to the use of these scores in daily practice.
omposition of the prognostic adenosine score: parsi-
ony versus accuracy. This score addresses a perceived
eed of clinicians by providing a validated prognostic score
hat may enhance physicians’ understanding of adenosine
PS results and optimize their incorporation into clinical
ecisions. An early question was whether to derive a
arsimonious score, hence simple to use and more likely to
e incorporated in practice, or to derive a more complex
core that would require software for calculation.
Although many advocate reporting of estimates of risk
25), this is a complex issue. Because non-nuclear data—
linical, historical, stress, and treatment information—add
ncrementally to MPS data (6–8), the risk associated with
ny specific MPS defect’s extent and severity varies widely
ith numerous clinical and historical characteristics, such as
ge, diabetes mellitus, and type of stress performed, which
ust be adjusted for in risk estimation. The prognostic
core demonstrates that various combinations of clinical,
tress test, and MPS data result in a similar score, thus a
imilar short-term risk; a younger patient with severe MPS
efects and an older, diabetic patient with less severe MPS
ay be at similar risk.
Furthermore, a post-test referral bias (usually associated
ith markedly lowered specificity and a mild increase in
ensitivity) also impacts prognostic MPS applications
12,26,27). Aggressive revascularization strategies in pa-
ients with extensive ischemia lower the risk of adverse
ost-MPS outcomes. Although this bias cannot be com-
letely eliminated, the inclusion of patients treated with
ither medical therapy or early revascularization in prognos-
ic analyses may permit enhanced estimation of risk by
eans of expressing risks with the two therapeutic ap-
roaches.
Although parsimony and simplification would enhance
he application of a prognostic score, it would also adversely
ffect the ability to accurately estimate risk for individual
atients. Predicting risk based solely on the relationship
etween perfusion results and outcomes would result in a
is-estimate of risk in many patients. As the current study
hows, risk assessment is enhanced with increasing score
omplexity. As a compromise, we also include a more
implified score in an attempt to partially overcome this
imitation.
rediction of risk versus benefit. The use of this score to
enerate estimates of risk with medical therapy and with gevascularization introduces an important concept. Identi-
ying therapeutic benefit may be of greater importance than
imply estimating risk after MPS. For example, a patient
ith severe and extensive MPS abnormalities would clearly
e at high risk. However, if these defects are fixed (nonre-
ersible), this patient is not likely to benefit from revascu-
arization. Alternatively, with increasing amounts of induc-
ble ischemia, the potential benefit from revascularization
ncreases (2). By distinguishing patients at high risk with
ittle or no benefit from patients at high risk with substantial
otential benefit, we are providing a more sound clinical
pplication of MPS and improving patient care and the role
PS plays in practice.
omposition of prognostic adenosine score. We identi-
ed nine covariates in the prognostic score. With respect to
linical data, patient age, presence of diabetes mellitus,
esting ECG abnormalities, and dyspnea as a presenting
ymptom were included. Both fixed and reversible defects
ere included in the model. The inclusion of these two
ariables, rather than the use of the extent and severity of
tress defects, was due to the overwhelming strength of fixed
efects as a predictor of cardiac death, as well as the
tatistically significantly interaction between the presence of
nducible ischemia and the use of early revascularization as
predictor of lower risk of cardiac death. Both rest and peak
eart rates during adenosine stress were predictors in this
odel. A number of variables were not predictors of cardiac
eath in the current study—in particular, a history of
AD/revascularization, ST-segment change during adeno-
ine stress, and use of anti-ischemic medications, despite
enerally being considered incremental predictors of this
nd point. It is possible that the inclusion of covariates
reviously not considered, such as use of early revascular-
zation, rest and peak heart rates and fixed and reversible
efects as separate variables, provided information similar to
hese variables.
tudy limitations. STATISTICAL AND CLINICAL. We de-
ived a prognostic score in an observational data series using
stablished multivariate statistical techniques. The use of
his approach enhanced the likelihood that the most pre-
ictive variables and their weights were identified; the
plit-set approach ensured the reproducibility of the derived
core. Nonetheless, this score will only be considered fully
alidated after testing in other cohorts consisting of geo-
raphically and clinically diverse patients.
The impact of various selection biases, spurious observa-
ions, and single-site data cannot be ignored as limitations.
he patients in this study were referred for MPS, and the
esults may not be generalizable to all such patients at all
enters. To limit the potential bias from referral to early
evascularization, we did not censor patients undergoing
arly revascularization but adjusted for revascularization in
he analysis. The loss to follow-up in the current study is
reater than that we have previously reported (6% vs.5%),
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March 1, 2005:722–9 Adenosine Stress MPS Prognostic Scoreossibly due to our cohort’s greater age (mean 73 years), and
ay have introduced an additional bias.
ECHNICAL. Scintigraphic studies in the current work were
nterpreted by experienced observers using a standardized,
emi-quantitative approach to visual interpretation, which
e have developed and have documented to be highly
eproducible (14). We have expressed perfusion images
esults as % myocardium rather than a semiquantitive
ummed score (7), thereby providing a measure with intu-
tive implications not possible with the unit-less summed
cores, which can be applied to scoring systems using
arying numbers of segments (e.g., 20,17,13), and is appli-
able to quantitative methods that report abnormalities as
ercent myocardium (28). Unpublished data from our site
ndicate that semiquantitative percent myocardium esti-
ates closely agree with quantitative analysis (r2 0.94).
onclusions. The results of the current study describe an
nternally validated prognostic adenosine stress MPS score
ncorporating clinical, stress test, and MPS data. This score
ields enhanced stratification over MPS results alone and,
y maximizing the prognostic information extracted from
denosine stress studies, may enhance the value of these
ests as a part of testing strategies.
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